ACM
TRML

ADAR1 Capital Management’s Tourmaline Bio TRML Stock Holding History

ADAR1 Capital Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,260
Closed -$289K – 301
2024
Q3 		$289K Sell
11,260
-9,800
-47% -$164K 0.05% 144
2024
Q2 		$271K Buy
21,060
+9,500
+82% +$153K 0.05% 128
2024
Q1 		$265K Buy
+11,560
New +$408K 0.06% 109

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

ADAR1 Capital Management's TRML Position: Q4 2024 in Review

ADAR1 Capital Management sold out of Tourmaline Bio (TRML) in Q4 2024, closing a stake of 11,260 shares — an estimated $289K sold.

ADAR1 Capital Management first reported a position in TRML in Q1 2024 and held it in 3 quarters. The position peaked at $289K in Q3 2024. 101 funds tracked by Wall St. Rank hold TRML as of Q4 2024.

  • ADAR1 Capital Management reported no remaining Tourmaline Bio position as of Q4 2024 after selling out during the quarter.
  • ADAR1 Capital Management sold 11,260 Tourmaline Bio shares in Q4 2024, an estimated $289K.
  • ADAR1 Capital Management first reported a position in Tourmaline Bio in Q1 2024 and held it in 3 quarters.
  • ADAR1 Capital Management's Tourmaline Bio position peaked at $289K in Q3 2024.
  • 101 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2024.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.